2015 American Transplant Congress
Improving the Predictive Value of the Virtual Crossmatch: Is the C1Q Assay Needed?
The criteria for reporting unacceptable HLA antigens of renal transplant candidates differ greatly between transplant centers. In the attempt to refine these criteria, the experience…2015 American Transplant Congress
Risk of HLA Antibody Sensitization in Pediatric Heart Failure Patients Pre/Post Berlin VAD Procedure and Pre/Post Heart Transplantation
Baylor College of Medicine, Houston, TX; Texas Children's Hospital, Houston, TX.
The Berlin Heart Excor Ventricular Assist Device (Berlin VAD) was designed for use in children with heart failure. The Berlin VAD has allowed for successful…2015 American Transplant Congress
Bortezomib Treatment in Antibody Mediated Rejection After Kidney Transplantation
BackgroundSeveral studies demonstrated bortezomib therapy for antibody-mediated rejection (AMR) in renal transplants. However, the treatment efficacy according to target antigen or occurrence time of AMR…2015 American Transplant Congress
Are DQA Antibodies Real?
Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
Antibodies specific for HLA-DQ antigens appear to be increasing in frequency in the post-transplant period and are difficult to reduce effectively with desensitization protocols using…2015 American Transplant Congress
Outcome of Bortezomib/Plasmapheresis for the Sensitized Patient Awaiting Heart Transplant
Cedars-Sinai Heart Institute, Los Angeles, CA.
Purpose: Allosensitization of patients (pts) awaiting heart transplantation is a significant challenge as it prolongs the time to transplant, increases wait-list mortality and increases risk…2015 American Transplant Congress
Incidence of De Novo Donor Specific Antibodies in Kidney Transplant Recipients
The reported incidence and risk factors for the development of de novo donor specific antibodies (dnDSA) are variable. Although dnDSA is a negative predictor of…2015 American Transplant Congress
Differences in Reactivity of HLA-Specific Antibodies May Be Explained By Differences in Their Affinities for Selected Epitopes on HLA Proteins
Affinity of IgG immunoglobulins for antigen varies and matures within the evolution of immune responses. Affinity is likely to be different for different epitope-antibody interactions…2015 American Transplant Congress
Extended Analysis of Tocilizumab (anti-IL-6R) + Intravenous Immunoglobulin (IVIG) as Desensitization (DES) Agents for Reduction of Donor Specific Antibodies (DSA) in Patients Resistant to DES With IVIG + Rituximab
Kidney Transplant, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: IVIG+rituximab is an acceptable approach for DES with good outcomes. Despite this, ∼30% of patients fail DES, thus other approaches are needed. Options include…2015 American Transplant Congress
First Clinical Data With an Improved C1q-Luminex® Assay
1Nephrology, Charite Hospital, Berlin, Germany; 2HLA Laboratory, Charite Hospital, Berlin, Germany.
Background: Chronic allograft dysfunction remains the main obstacle for long-term success of kidney transplantation. Immunological factors, in particular HLA-antibodies, contribute to long-term allograft loss. Identification…2015 American Transplant Congress
Accurate Prediction of High-Resolution HLA-A, -B, -C, -DRB1 and -DQB1 Typing and Low-Resolution HLA-DQA1 Typing by Haplotype Analysis
Aim: Allele-specific HLA antibodies are commonly detected by Luminex single antigen bead assays in solid organ transplant recipients. However, high-resolution HLA typing for deceased donors…
American Transplant Congress abstracts